What is Forte Biosciences's market cap?

Forte Biosciences (FBRX) has a market capitalization of $1.6B and trades on NASDAQ.

Who are Forte Biosciences's competitors?

Forte Biosciences's key competitors include Artelo Biosciences, Inc. Common Stock, Fortrea Holdings Inc. Common Stock, Impact BioMedical, Inc., and others. These companies compete in similar markets and product categories.

What subsidiaries does Forte Biosciences have?

Forte Biosciences's subsidiaries include Tocagen, Inc..

Where is Forte Biosciences headquartered?

Forte Biosciences is headquartered in United States of America and employs approximately 11 people. It has been publicly traded since 2020.

Forte Biosciences

FBRX

Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune and inflammatory diseases.

Market cap

$1.57B+1,159%

Table of contents

Earnings

Q1 2026 report

May 11, 2026

EPS-$1.24Miss by $0.08

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

EPS estimate-$0.92

Competitors

By market cap

BridgeBio Pharma$16.5B+87.7%

Fortrea Holdings Inc.$1.8B+192%

FBR

Forte Biosciences$1.6B+1,003%

Compass Therapeutics, Inc.$374.6M-15.3%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

SPR

Spruce Biosciences, Inc. $115.6M—

Impact BioMedical$46.6M-34.6%

Artelo Biosciences$3.5M-63.9%

By revenue growth

BridgeBio Pharma+355%

Fortrea Holdings Inc.-2.1%

By net margin

Fortrea Holdings Inc.-3.18%+34.4pp

BridgeBio Pharma-125.85%+405pp

Profile

Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune and inflammatory diseases. Its core value proposition centers on its proprietary monoclonal antibody platform, specifically targeting the CD122 subunit to modulate T cell and NK cell activity while sparing regulatory T cells.

Competitive position

Forte is a clinical-stage developer competing against established pharmaceutical firms and specialized biotechs in the high-growth autoimmune and dermatology markets.

GeographiesUnited States

Customer segmentsPatients with autoimmune diseases, Clinical trial participants

Business modelResearch and Development, Biotechnology R&D

SuppliersContract Manufacturing Organizations (CMOs), Clinical Research Organizations (CROs), Raw material suppliers

CustomersSpecialty pharmacies, Hospitals, Government health programs, Commercial insurers

CountryUnited States of America

Listed2020

Employees11.0

CEOPaul A. Wagner

SectorHealthcare

IndustryBiotechnology

Websitefortebiorx.com

FilingsSEC EDGAR

Questions, answered.

What is Forte Biosciences's market cap?: Forte Biosciences (FBRX) has a market capitalization of $1.6B and trades on NASDAQ.
Who are Forte Biosciences's competitors?: Forte Biosciences's key competitors include Artelo Biosciences, Inc. Common Stock, Fortrea Holdings Inc. Common Stock, Impact BioMedical, Inc., and others. These companies compete in similar markets and product categories.
What subsidiaries does Forte Biosciences have?: Forte Biosciences's subsidiaries include Tocagen, Inc..
Where is Forte Biosciences headquartered?: Forte Biosciences is headquartered in United States of America and employs approximately 11 people. It has been publicly traded since 2020.